Anti-Human CD194 (CCR4) (Mogamulizumab) HRP, Clone: [KW-0761], Monoclonal

Artikelnummer: ABI-12-8021
Artikelname: Anti-Human CD194 (CCR4) (Mogamulizumab) HRP, Clone: [KW-0761], Monoclonal
Artikelnummer: ABI-12-8021
Hersteller Artikelnummer: 12-8021
Alternativnummer: ABI-12-8021-100UG
Hersteller: Abeomics
Wirt: Human
Kategorie: Sonstiges
Applikation: ELISA
Spezies Reaktivität: Human
Immunogen: Humanization of mouse anti-CCR4 mAb7.
Alternative Synonym: CD194, CKR-4, CCR-4, CCR4, K5-5
Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only. Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1infected cells and the levels of inflammatory markers related to HTLV-1Associated Myelopathy.3
Klonalität: Monoclonal
Klon-Bezeichnung: [KW-0761]
Target-Kategorie: CD194
Antibody Type: Recombinant Antibody
Application Verdünnung: The suggested concentration for Mogamulizumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.ELISA